Pandrug-resistant (PDR) Klebsiella pneumoniae: Introduction, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

• Organism: Gram-negative, encapsulated, facultative anaerobic, rod-shaped bacterium.
• Epidemiology: Major cause of healthcare-associated infections (HAIs) like pneumonia, bloodstream infections, and UTIs.
• PDR Definition: Non-susceptible to all antimicrobial agents across all clinical categories (beta-lactams, carbapenems, aminoglycosides, fluoroquinolones, polymyxins, and tigecycline).

Pathogenicity & Virulence Factors

• Capsular Polysaccharide (CPS): Inhibits phagocytosis and complement-mediated killing.
• Lipopolysaccharide (LPS): Acts as an endotoxin, triggering severe inflammatory responses.
• Fimbriae (Types 1 & 3): Mediate adherence to host tissues and synthetic surfaces for biofilm formation.
• Siderophores: Scavenge iron from host proteins to support bacterial metabolism.
• Resistance Drivers: Driven by carbapenemase production (KPC, NDM, OXA-48), porin loss (OmpK35/36), and mgrB gene mutations (colistin resistance).

 Laboratory Diagnosis

• Microscopy: Gram-negative bacilli.
• Culture: Large, pink, characteristically mucoid colonies on MacConkey agar due to lactose fermentation.

• Biochemical Profile: Catalase-positive, oxidase-negative, indole-negative, citrate-positive, and urease-positive.
• Susceptibility Testing: Handled via automated systems or broth microdilution (essential for colistin).
• Molecular Diagnostics: PCR and Next-Generation Sequencing (NGS) for the isolation of specific carbapenemase genes.

Therapeutic Management Strategies

• High-Dose Synergy: Combining maximal drug doses via prolonged infusions (e.g., double carbapenems).
• Novel Inhibitors: Aztreonam-avibactam or ceftazidime-avibactam combos (targeted to specific enzyme profiles).
• Salvage Therapies: Use of novel agents like Cefiderocol or experimental bacteriophage therapy.

Prevention and Infection Control

• Hand Hygiene: Compliance with standard alcohol-based hand rub protocols.
• Contact Isolation: Mandatory single-room isolation with dedicated gowns and gloves.
• Decontamination: Intensive environmental disinfection of high-touch clinical surfaces.
• Stewardship: Strict management of broad-spectrum and last-resort antibiotics.
• Active Surveillance: Routine rectal swab screening to identify and isolate asymptomatic carriers.

Keynotes

• PDR vs. XDR: Extensive drug resistance (XDR) leaves a few options; PDR leaves zero conventional choices.

• Testing Pitfall: Disk diffusion is invalid for colistin testing; always request broth microdilution.
• Hypervirulent Shift: Watch for “convergent” strains combining PDR with hypervirulence (hvKP), affecting healthy individuals.

Further Readings

1. https://www.researchgate.net/publication/389770138_Mechanisms_of_Antimicrobial_Resistance_in_Klebsiella_Advances_in_Detection_Methods_and_Clinical_Implications
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10886558/
3. https://www.tandfonline.com/doi/full/10.2147/IJGM.S548733
4. https://www.dovepress.com/mechanisms-of-antimicrobial-resistance-in-klebsiella-advances-in-detec-peer-reviewed-fulltext-article-IDR
5. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1691215/full
6. https://pubmed.ncbi.nlm.nih.gov/36912811/
7. https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(17)30499-8/fulltext
8. https://academic.oup.com/jac/article/81/3/dkag064/8496198